Cite
Tate M, Higgins GC, De Blasio MJ, et al. Correction to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart. Cardiovasc Drugs Ther. 2020;34(2):223doi: 10.1007/s10557-019-06929-2.
Tate, M., Higgins, G. C., De Blasio, M. J., Lindblom, R., Prakoso, D., Deo, M., Kiriazis, H., Park, M., Baeza-Garza, C. D., Caldwell, S. T., Hartley, R. C., Krieg, T., Murphy, M. P., Coughlan, M. T., & Ritchie, R. H. (2020). Correction to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart. Cardiovascular drugs and therapy, 34(2), 223. https://doi.org/10.1007/s10557-019-06929-2
Tate, Mitchel, et al. "Correction to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart." Cardiovascular drugs and therapy vol. 34,2 (2020): 223. doi: https://doi.org/10.1007/s10557-019-06929-2
Tate M, Higgins GC, De Blasio MJ, Lindblom R, Prakoso D, Deo M, Kiriazis H, Park M, Baeza-Garza CD, Caldwell ST, Hartley RC, Krieg T, Murphy MP, Coughlan MT, Ritchie RH. Correction to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart. Cardiovasc Drugs Ther. 2020 Apr;34(2):223. doi: 10.1007/s10557-019-06929-2. PMID: 32062792; PMCID: PMC7645541.
Copy
Download .nbib